Safety and Efficacy of AZD0120, a BCMA/CD19 Dual-Targeting CAR T-cell Therapy, in relapsed/refractory Multiple Myeloma: Preliminary Results from the DURGA-1 phase 1b/2 Study

Transplantation and Cellular Therapy 2026

View at publisher
Authors: Shambavi Richard, Mahmoud Gaballa, Tara K Gregory, Saurabh Chhabra, Larry D. Anderson, Luciano J. Costa, Caitlin L. Costello, Scott Ryan Goldsmith, Doris K. Hansen, Sridevi Rajeeve, Shaji Kumar, Aravind Ramakrishnan
+8 more Minoo Battiwalla, Ajay K. Nooka, Hira Ghazal Shaikh, Meiyue Hong, Steven Wang, Patricia Cheung, Liang Li, Binod Dhakal
DOI: 10.1016/j.jtct.2025.12.054
Cited by: 0

Fields of Study & Subjects

CAR-T cell therapy research Multiple Myeloma Research and Treatments Immunotherapy and Immune Responses

Publication details

Journal / source
Transplantation and Cellular Therapy
Volume
32
Issue
2
Pages
S33–S33
Publication date
1 February 2026
Language
EN